<DOC>
	<DOCNO>NCT00401180</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel temozolomide treat patient metastatic cancer .</brief_summary>
	<brief_title>Docetaxel Temozolomide Treating Patients With Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity profile , dose-limiting toxicity , maximum tolerate dose docetaxel temozolomide ( TMZ ) patient metastatic cancer . Secondary - Determine activity docetaxel TMZ patient . OUTLINE : This dose-escalation study . Patients receive docetaxel IV 1 hour day 1 , 8 , 15 oral temozolomide daily day 1-21 . Treatment repeat every 28 day 1 year absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos docetaxel temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . A total 6 patient receive treatment MTD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis nonhematologic malignancy refractory standard therapy OR standard therapy available Measurable ( CT scan ) evaluable disease If palliative radiotherapy administer , measurable disease must outside radiation port Prior brain metastasis allow provide definitely treated externalbeam radiotherapy , gamma knife , surgical resection clinically stable Repeat MRI CT scan must demonstrate stabilization disease 4 week definitive therapy complete AND must requirement dexamethasone No active CNS metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 4 month Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL ( epoetin alfa and/or transfusion allow ) Creatinine ≤ 2 mg/dL Bilirubin normal PT normal , unless patient warfarin prior deep vein thrombosis pulmonary embolus , require INR maintain 2.0 3.0 Sodium potassium normal AST ALT ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN No decompensated cardiac arrhythmia severe cardiovascular disease ( i.e. , New York Heart Association [ NYHA ] class IIIIV heart disease ) Patients clinically stable NYHA class III IV heart disease require cardiac clearance No peripheral neuropathy &gt; grade 1 No infection require IV antibiotic within past 14 day No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No HIV positivity No hepatitis B surface antigen hepatitis C antibody positivity No pulmonary embolus within past 3 week Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No 3 course prior immunotherapy and/or chemotherapy metastatic disease Interferon alfa adjuvant set consider course prior therapy Patients relapse adjuvant interferon alfa must therapy ≥ 3 week No prior stem cell organ transplantation More 21 day since prior immunotherapy chemotherapy At least 21 day since prior hormonal therapy ( except luteinizing hormonereleasing hormone [ LHRH ] agonist ) radiotherapy recover More 21 day since prior surgery require general anesthesia No concurrent radiotherapy Concurrent LHRH agonist therapy allow Concurrent physiologic replacement steroid allow No concurrent chemotherapy thalidomide No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) study chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>